MedPath
FDA Approval

Evista

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Eli Lilly and Company
DUNS: 006421325
Effective Date
May 19, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Raloxifene(60 mg in 1 1)

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Evista

Product Details

NDC Product Code
0002-4184
Application Number
NDA020815
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
May 19, 2023
Code: 4F86W47BR6Class: ACTIBQuantity: 60 mg in 1 1
Carnauba WaxInactive
Code: R12CBM0EIZClass: IACT
Crospovidone, UnspecifiedInactive
Code: 2S7830E561Class: IACT
Lactose monohydrateInactive
Code: EWQ57Q8I5XClass: IACT
Hypromellose, UnspecifiedInactive
Code: 3NXW29V3WOClass: IACT
Povidone, UnspecifiedInactive
Code: FZ989GH94EClass: IACT
Magnesium stearateInactive
Code: 70097M6I30Class: IACT
Anhydrous lactoseInactive
Code: 3SY5LH9PMKClass: IACT
Polyethylene glycol 400Inactive
Code: B697894SGQClass: IACT
Titanium dioxideInactive
Code: 15FIX9V2JPClass: IACT
Polysorbate 80Inactive
Code: 6OZP39ZG8HClass: IACT
Propylene glycolInactive
Code: 6DC9Q167V3Class: IACT
© Copyright 2025. All Rights Reserved by MedPath